tbuckley/cabot-search huggingface dataset:
Contrasting evolutionary genome dynamics between domesticated and wild yeasts
Authors: Jia-Xing Yue, Jing Li, Louise Aigrain, Johan Hallin, Karl Persson, Karen Oliver, Anders Bergström, Paul Coupland, Jonas Warringer, Marco Cosentino Lagomarsino, Gilles Fischer, Richard Durbin, Gianni Liti
Journal: Nature Genetics (2017)

Structural rearrangements have long been recognized as an important source of genetic variation, with implications in phenotypic diversity and disease, yet their detailed evolutionary dynamics remain elusive. Here we use long-read sequencing to generate end-to-end genome assemblies for 12 strains representing major subpopulations of the partially domesticated yeast Saccharomyces cerevisiae and its wild relative Saccharomyces paradoxus. These population-level high-quality genomes with comprehensive annotation enable precise definition of chromosomal boundaries between cores and subtelomeres and a high-resolution view of evolutionary genome dynamics. In chromosomal cores, S. paradoxus shows faster accumulation of balanced rearrangements (inversions, reciprocal translocations and transpositions), whereas S. cerevisiae accumulates unbalanced rearrangements (novel insertions, deletions and duplications) more rapidly. In subtelomeres, both species show extensive interchromosomal reshuffling, with a higher tempo in S. cerevisiae. Such striking contrasts between wild and domesticated yeasts are likely to reflect the influence of human activities on structural genome evolution.
Hiding in Plain Sight—Resurrecting the Power of Inspecting the Patient
Authors: Shlok Gupta, Sanjay Saint, Allan S. Detsky
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
A phase 1, open-label, dose-escalation study of SNX-5422 plus carboplatin and paclitaxel in subjects with advanced lung cancers.
Authors: Martin Gutierrez, Giuseppe Giaccone, Harry D. Harper, Stephen V. Liu, Bruno Fang, Jimmy Ruiz, James M Hinson, Everardus Otto Orlemans, Alexander E. Drilon
Journal: Journal of Clinical Oncology (2015)

e19033 Background: SNX-5422 is an orally bioavailable pro-drug of SNX-2112, a highly potent and selective Hsp90 inhibitor with preclinical anti-tumor activity in lung cancer models and synergy with platinum and taxane compounds. Carboplatin/paclitaxel is a commonly used treatment for advanced lung cancer. This phase 1 study examined SNX-5422 plus carboplatin/paclitaxel followed by SNX-5422 maintenance therapy in pts with advanced lung cancers. Methods: Eligible pts had advanced NSCLC (EGFR wild-type or non-sensitizing mutation, ALK wild-type) or extensive stage SCLC and up to one prior line of chemotherapy. Pts received paclitaxel (175 mg/m2) and carboplatin (AUC 5) q3w up to 4 courses and SNX-5422 qod (starting at 50 mg/m2), 21 of 28 days, with a standard 3+3 dose escalation rule during the combination followed by SNX-5422 (100 mg/m2 qod) monotherapy for maintenance until disease progression. Safety and tolerability were evaluated to determine the maximum tolerated dose (MTD) and pharmacokinetics of SNX-2112. Results: Since August 2013, 15 pts have been enrolled. No dose-limiting toxicities (DLTs) for the combination were reported for SNX-5422 up to 75 mg/m2. The SNX-5422 Maximum Tolerated Dose was determined at 100 mg/m2 for the combination with one grade 3 DLT of diarrhea. Adverse events possibly related to the combination in ≥ 2 pts were diarrhea, nausea, fatigue, neutropenia, alopecia, mostly graded 1 or 2, except for grade 3 neutropenia (2), diarrhea (2), and nausea (1). Of 8 NSCLC pts evaluable for objective response 4 had partial response, 3 stable disease and 1 disease progression as best response during the combination part. Six of 8 NSCLC patients completing the maximum of 4 courses of carboplatin/paclitaxel/ SNX-5422 went onto maintenance. Of 3 SCLC, pts 2 had stable disease and 1 disease progression as best response. Five NSCLC pts are ongoing and with the dose escalation phase completed, the study continues to enroll new NSCLC pts in the expansion cohort. Conclusions: The addition of SNX-5422 to carboplatin (AUC 5)/paclitaxel (175 mg/m2) was well-tolerated at doses up to 100 mg/m2. Preliminary efficacy of this triplet combination in NSCLC is encouraging. Clinical trial information: NCT01892046.
Retraction Notice to: Impairment of Central Leptin-Mediated PI3K Signaling Manifested as Hepatic Steatosis Independent of Hyperphagia and Obesity
Authors: James P. Warne, Farzad Alemi, Alison S. Reed, Jillian M. Varonin, Helen Chan, Merisa L. Piper, Mark E. Mullin, Martin G. Myers, Carlos U. Corvera, Allison W. Xu
Journal: Cell Metabolism (2015)
Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma
Authors: Sumanta K. Pal, Guru Sonpavde, Neeraj Agarwal, Nicholas J. Vogelzang, Sandy Srinivas, Naomi B. Haas, Sabina Signoretti, Bradley A. McGregor, Jeremy Jones, Richard B. Lanman, Kimberly C. Banks, Toni K. Choueiri
Journal: European Urology (2017)
Early Palliative Care in Advanced Illness
Authors: Anand S. Iyer, Marie Bakitas
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Erratum: Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing
Authors: R K Thomas, E Nickerson, J F Simons, P A Jänne, T Tengs, Y Yuza, L A Garraway, T LaFramboise, J C Lee, K Shah, K O'Neill, H Sasaki, N Lindeman, K-K Wong, A M Borras, E J Gutmann, K H Dragnev, R DeBiasi, T-H Chen, K A Glatt, H Greulich, B Desany, C K Lubeski, W Brockman, P Alvarez, S K Hutchison, J H Leamon, M T Ronan, G S Turenchalk, M Egholm, W R Sellers, J M Rothberg, M Meyerson
Journal: Nature Medicine (2006)
Estimated Cost of Emergency Sunburn Visits—Validation of <i>ICD-9-CM</i> Search Criteria
Authors: Fan Di Xia, Cara Joyce, Arash Mostaghimi
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
AN EPIDEMIOLOGIC COMPARISON OF INJURIES TO SKIERS AND SNOWBOARDERS TREATED AT UNITED STATES EMERGENCY DEPARTMENTS, 2000–2015
Authors: Lauren Pierpoint, Blake Volkmer, Dawn Comstock, Khodaee Morteza
Journal: British Journal of Sports Medicine (2017)

Background Skiing and snowboarding, popular competitive and recreational sports, can be associated with significant injury. In 2014/15, there were 53.6 million ski- and snowboarder-visits to United States (US) resorts. Previous studies of skiing and snowboarding injuries have been conducted, but studies evaluating injury patterns over long periods of time are needed to drive effective injury prevention efforts. Objective Compare patterns of skiing and snowboarding injuries presenting to emergency departments (EDs) from 2000–2015. Design Retrospective descriptive epidemiology. Setting US EDs. Participants Patients presenting with skiing or snowboarding injuries. Assessment of Risk Factors Case reports were obtained from a large national hospital surveillance system that included sample weighting factors enabling calculation of national estimates. Main Outcome Measurements Injury incidence and characteristics. Results From 2000–2015, 36,145 injured skiers (48.0%) and snowboarders (52.0%) presented to US EDs representing an estimated 1,660,514 injuries nationwide. Males represented most skiing (59.7%) and snowboarding (73.2%) injuries. Skiers were older than snowboarders (mean 31.7 vs. 19.7 years; p&lt;0.01); patients aged 10–19 represented more snowboarding (57.8%) than skiing (31.6%) injuries. Common diagnoses included sprains/strains (skiers=32.2%; snowboarders=24.7%) and fractures (skiers=27.7%, snowboarders=35.7%). Knees (20.8%) and shoulders (14.4%) were most commonly injured in skiers; wrists (20.1%) and shoulders (15.9%) in snowboarders. Individuals most often hospitalized following ED presentation were male (74.8%) and 15–19 years old (20.5%). Compared to all other injuries, fractures (OR=3.66, 95% CI=3.10–4.37) and head injuries (OR=2.10, 95% CI=1.44–3.06) more often resulted in hospitalization. After controlling for age, sex, body part, and diagnosis, skiers were more likely to be hospitalized than snowboarders (OR=1.43, 95% CI=1.16–1.77). Conclusions Injury patterns and severity vary between skiers and snowboarders. Understanding the epidemiology of injuries presenting to EDs can help guide prehospital care and medical coverage allocation for resorts and event organizers, as well as identifying areas for targeted injury prevention efforts.
Unmet need for surgery in South Asia
Authors: Sanjay Nagral, Maharra Hussain, Sarder A Nayeem, Ranjan Dias, S Ather Enam, Samiran Nundy
Journal: BMJ (2017)

Despite increased specialisation and technology, surgical care in the world’s most populous region is inequitable and remains inaccessible to most people, say <b>Sanjay Nagral and colleagues</b>
TCTAP A-160 Novel Technique to Avoid Perforation of the Right Ventricle by the Temporary Pacing Lead During Transcatheter Aortic Valve Implantation
Authors: Makoto Tanaka, Ryo Yanagisawa, Fumiaki Yashima, Takahide Arai, Yusuke Watanabe, Toru Naganuma, Shinichi Shirai, Motoharu Araki, Norio Tada, Futoshi Yamanaka, Hideyuki Shimizu, Keiichi Fukuda, Masanori Yamamoto, Kentaro Hayashida
Journal: Journal of the American College of Cardiology (2017)
Three design aspects for high quality post-marketing cohort studies
Authors: Michael Fralick, Aaron S Kesselheim
Journal: BMJ (2017)

Spelsberg and colleagues showed that ascertaining the results of post-marketing safety studies is challenging.1 In the US and Europe, brand name drug manufacturers are required to summarise data from post-marketing studies and submit them to the regulatory authority.2 Aspects of these reports should be made publicly available to inform the medical community about important emerging data and allow the scientific community to evaluate …
Ruxolitinib for Myelofibrosis Patients Relapsing after Allogeneic Hematopoietic Transplantation
Authors: Dietlinde Janson, Francis A Ayuk, Christine Wolschke, Maximilian Christopeit, Anita Badbaran, Ute-Marie von Pein, Andre van Randenborgh, Nicolaus Kroeger
Journal: Blood (2016)
Metronomic chemotherapy with capecitabine and oral cyclophosphamide in combination with bevacizumab in metastatic breast cancer (mbc): Evidence of activity of an antiangiogenic treatment
Authors: A. Rocca, S. Dellapasqua, E. Pietri, M. Dettori, C. D’Alessandro, R. Ghisini, A. Colombo, A. Goldhirsch, M. Colleoni
Journal: Journal of Clinical Oncology (2007)

11501 Background: Metronomic chemotherapy has shown efficacy in patients (pts) with MBC. Laboratory and clinical studies suggest that the combination with a specific antiangiogenic drug may be particularly effective. Methods: We evaluated the activity and biological effects of low dose continuous oral Capecitabine (500 mg PO TID) and Cyclophosphamide (50 mg PO QD) plus Bevacizumab (10 mg/Kg Q 2 weeks) in a two stage phase II trial in MBC pts, who received =3 lines of chemotherapy for advanced disease. Planned sample size is 46 pts. Results: To date, 26 patients have been enrolled on the study and 23 are evaluable. Pts characteristics: 1/2/=3 sites of metastatic disease 6/9/11 pts; dominant sites of disease soft tissues/bone/viscera 1/11/22; previous treatment for MBC: endocrine/chemo/trastuzumab 13/21/1 pts (=2 lines 25). Results: there were 1 CRs (4.3%), 10 PRs (43.5%), 6 SD (26.1%), and 6 PD (26.1%), for an overall response rate of 48% (exact 95% CI 27–69%). Median progression free survival was 6 months (+). Grade 3 side effects: 6 hypertension , 1 leucopenia , 2 neutropenia , 2 transaminitis (both with liver metastases). No patient was withdrawn from the study due to side effects, and hypertension was manageable with adequate therapy. Data on median circulating endothelial cells (CECs) will be available. Conclusions: Metronomic chemotherapy with capecitabine and cyclophosphamide in combination with bevacizumab has clinical activity and low toxicity in advanced breast cancer. No significant financial relationships to disclose.
Bone marrow histology for the diagnosis of essential thrombocythemia in children: a multicenter Italian study
Authors: Maria Caterina Putti, Marco Pizzi, Irene Bertozzi, Elena Sabattini, Concetta Micalizzi, Piero Farruggia, Ugo Ramenghi, Simone Cesaro, Giovanna Russo, Edoardo Peroni, Massimo Rugge, Fabizio Fabris, Maria Luigia Randi
Journal: Blood (2017)
Serum Interferon-inducible Protein-10 is Associated with Replicative Status of Hepatitis D Virus, and Correlates with Hepatitis D RNA Levels, but does not Predict Treatment Outcome
Authors: Sarah Hughes, Ivana Carey, Matthew J. Bruce, Mary Horner, Dazhuang Shang, Ian Fletcher, Abid Suddlel, Kosh Agarwal, Phillip Harrison
Journal: Hepatology (2012)
Re: Richard J. Sylvester, Steven E. Canfield, Thomas B.L. Lam, et al. Conflict of Evidence: Resolving Discrepancies When Findings from Randomized Controlled Trials and Meta-analyses Disagree. Eur Urol 2017;71:811–9
Authors: Philipp Dahm, Vikram Narayan, Jae Hung Jung
Journal: European Urology (2017)
Antagonism of etoposide cytotoxicity for neuroblastoma by retinoic acid is mediated by the anti-apoptotic bcl-2 family proteins.
Authors: Michael Hadjidaniel, C. Reynolds
Journal: Cancer Research (2007)

525  Retinoic acid (as 13-cis-retinoic acid = 13-cis-RA) is given at completion of cytotoxic therapy to control minimal residual disease in neuroblastoma. In acute promyelocytic leukemia, retinoic acid (as all-trans-retinoic acid = ATRA) was most effective when combined directly with cytotoxic chemotherapy. We evaluated the interaction between retinoic acid and cytotoxic chemotherapy in neuroblastoma cell lines and its relation to the bcl-2 family of proteins. Neuroblastoma cell lines (SMS-KCNR, SMS-LHN, SMS-SAN, CHLA-90, CHLA-79) were tested for cytotoxic response to drugs + ATRA or 13-cis-RA with a fluorescence-based digital imaging microscopy cytotoxicity assay (DIMSCAN). Apoptosis was assessed as DNA fragmentation and sub-genomic DNA content by flow cytometry; loss of mitochondrial membrane potential employed flow cytometryand the fluorochrome JC-1. Real-time quantitative RT-PCR (TAQMAN) was used to measure mRNA expression; Western blot was used to follow the intrinsic apoptotic pathway. Direct combination of 13-cis-RA or ATRA with etoposide, topotecan, carboplatin, cisplatin, melphalan and doxorubicin markedly antagonized the cytotoxicity of those agents for all tested neuroblastoma cell lines, increasing the fraction of cell survival by 1 to 3 logs. The concentration of drugs lethal for 99% of cells (LC99) was increased by 13-cis-RA from clinically achievable levels to non-achievable levels: 100 to 300-fold (doxorubicin) to > 1000-fold (cisplatin and etoposide). 13-cis-RA protected cells from late apoptosis, defined as DNA fragmentation and loss of membrane integrity, in response to etoposide. By quantitative RT-PCR, 13-cis-RA increased the expression of bcl-2 and bcl-xL, but decreased the expression of MYCN (p>0.03). Western blot data showed that 13-cis-RA pre-treated cells activated p53, but did not release Cytochrome c in response to etoposide. Pre-treatment of neuroblastoma cell lines with 13-cis-RA reduced the fraction of cells with loss of mitochondrial membrane potential in response to etoposide from 38% to 8% (basal level = 12%), but this was restored to 52% by a small molecule inhibitor of the bcl-2 family of proteins (ABT-737). Similar data were obtained for early apoptosis (at 16 hrs). 13-cis-RA pre-treatment decreased apoptotic (sub-G1) cells in response to etoposide from 58% to 18% (basal 17%), treating with ABT-737 reversed the antagonistic effect resulting in 74% apoptosis. Directly combining retinoic acid with cytotoxic chemotherapy in neuroblastoma markedly reduced the cytotoxic effect of the chemotherapy, mediated at least in part via the anti-apoptotic bcl-2 family of proteins.
TCTAP A-021 Prognostic Value of Coronary No-reflow Phenomenon After Primary PCI in Patients with STEMI
Authors: Batmyagmar Khuyag, Surenjav Chimed, Amarjargal Baldandorj, Lkhagvasuren Zundui, Narantuya Davaakhuu
Journal: Journal of the American College of Cardiology (2017)
Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002–2012
Authors: Elizabeth J. Mayer-Davis, Jean M. Lawrence, Dana Dabelea, Jasmin Divers, Scott Isom, Lawrence Dolan, Giuseppina Imperatore, Barbara Linder, Santica Marcovina, David J. Pettitt, Catherine Pihoker, Sharon Saydah, Lynne Wagenknecht
Journal: New England Journal of Medicine (2017)

Diagnoses of type 1 and type 2 diabetes in youths present a substantial clinical and public health burden. The prevalence of these diseases increased in the 2001-2009 period, but data on recent incidence trends are lacking.
Rod-Shaped Neural Units for Aligned 3D Neural Network Connection
Authors: Midori Kato‐Negishi, Hiroaki Onoe, Akane Ito, Shoji Takeuchi
Journal: Advanced Healthcare Materials (2017)

This paper proposes neural tissue units with aligned nerve fibers (called rod‐shaped neural units) that connect neural networks with aligned neurons. To make the proposed units, 3D fiber‐shaped neural tissues covered with a calcium alginate hydrogel layer are prepared with a microfluidic system and are cut in an accurate and reproducible manner. These units have aligned nerve fibers inside the hydrogel layer and connectable points on both ends. By connecting the units with a poly(dimethylsiloxane) guide, 3D neural tissues can be constructed and maintained for more than two weeks of culture. In addition, neural networks can be formed between the different neural units via synaptic connections. Experimental results indicate that the proposed rod‐shaped neural units are effective tools for the construction of spatially complex connections with aligned nerve fibers in vitro.
Cripto-1 acts as a functional marker of cancer stem-like cells and predicts prognosis of the patients in esophageal squamous cell carcinoma
Authors: Qiang Liu, Xiang Cui, Xi Yu, Bai-Shi-Jiao Bian, Feng Qian, Xu-gang Hu, Cheng-dong Ji, Lang Yang, Yong Ren, Wei Cui, Xia Zhang, Peng Zhang, Ji Ming Wang, You-hong Cui, Xiu-wu Bian
Journal: Molecular Cancer (2017)

Esophageal squamous cell carcinoma (ESCC) is highly malignant with highly invasive and metastatic capabilities and poor prognosis. It is believed that the ESCC cancer stem-like cells (ECSLCs) are critical for tumorigenicity, invasion and metastasis of ESCC. However, the properties of ECSLCs vary with different markers used in isolation, so that new and more effective markers of ECSLCs need to be identified. This study aimed to estimate the potentiality of Cripto-1 (CR-1) as an ECSLC surface marker and investigate the clinical significance of CR-1 expression in ESCC. ESCC cells with CR-1 high or CR-1low were obtained by flow cytometry then their self-renewal capability and tumorigenicity were compared by colony and limiting dilution sphere formation analysis in vitro and xenograft in nude mice in vivo, respectively. Knockdown of CR-1 expression in ESCC cells was conducted with short hairpin RNA. Cell migration and invasion were examined by scratch test and matrigel transwell assay, respectively. Metastatic capability of ESCC cells was assayed by a mouse tail vein metastasis model. The levels of CR-1 expression in cancerous and paired adjacent normal tissues were assessed by IHC and qRT-RCR. CR-1high subpopulation of ESCC cells isolated by FACS expressed high level of genes related to stemness and epithelial-mesenchymal transition (EMT), and possessed high capacities of self-renewal, tumorigenesis, invasion and metastasis. Suppression of CR-1 expression significantly reduced the expression of stemness- and EMT-related genes and the capabilities of self-renewal in vitro, tumorigenicity and metastasis in vivo in ESCC cells. In the clinical ESCC specimens, the expression levels of CR-1 in cancerous tissues were positively correlated to TNM stage, invasive depth, and lymph node metastasis. Cox regression analysis indicated that CR-1 was an independent indicator of prognosis. The expression of CR-1 was found overlapping with aldehyde dehydrogenase 1A1 (ALDH1A1), an intracellular marker for ESCLCs, in ESCC cell lines and specimens. CR-1 is a functional and cell surface ECSLC marker, and an independent prognostic indicator as well as a potential therapeutic target for ESCC.